Brevan Howard Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Brevan Howard Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$508K	Buy	+1,607	New	+$379K	﹤0.01%	1441

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's LGND Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,607 shares worth $508K. The stake represents ﹤0.01% of the portfolio and ranks #1441 among its holdings.

414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Brevan Howard Capital Management held 1,607 shares of Ligand Pharmaceuticals worth $508K as of Q2 2026.
Ligand Pharmaceuticals was a new Brevan Howard Capital Management position in Q2 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1441 holding.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.